Non-treated mice showed a maximum of 11 days survival following tumour injection which was increased to 60% of mice treated with elraglusib alone, 20% with PD-1 Ab alone and 50% when treated with a combination of both elraglusib and anti-PD-1 Ab. This evidence concerns the gene PDCD1 and neoplasm.